TITLE

Electronic tongue for pharmaceutical analytics: quantification of tastes and masking effects

AUTHOR(S)
Legin, Andrey; Rudnitskaya, Alisa; Clapham, David; Seleznev, Boris; Lord, Kevin; Vlasov, Yuri
PUB. DATE
September 2004
SOURCE
Analytical & Bioanalytical Chemistry;Sep2004, Vol. 380 Issue 1, p36
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The organoleptic aspects of pharmaceutical formulations affect their acceptability to tile patient and hence can have an important effect on concordance with treatment. Objective evaluation of these aspects, particularly the taste of the formulation and the drug substance it contains, is difficult. Whilst volunteer taste panels can be used to good effect their utility is limited. particularly during very early stage development when the toxicological profile of the active pharmaceutical ingredient (API) is yet to be established in detail. A potentiometric “electronic tongue” has been applied to analyse a variety of 41 individual substances and mixtures of particular interest for pharmaceutical research and development. The electronic tongue (ET) was capable of discriminating between substances with different taste modalities and could also distinguish different substances eliciting the same basic taste; the ET is promising in terms of quantifying the content of each substance and has an ability to detect nuances of the basic taste (e.g. lingering or short-lived). After calibration the electronic tongue was successfully applied to predicting bitterness strength of binary mixtures with a sweetener in terms of “apparent” or “perceived” quinine content. In order to render a formulation palatable it is often necessary to mask the (usually bitter) taste of the API by the addition of masking agents such as sweeteners and flavours. The ET proved capable of distinguishing between formulations with different levels of sweetener and/or flavour in a manner that was consistent with their masking efficiency as perceived by a small human taste panel. A suitably calibrated ET could have the benefit of providing the pharmaceutical formulator with reliable data concerning the taste of the product quickly and with a reduced need to ask volunteers to taste active pharmaceutical samples. Early development activities could be facilitated when human tasting is usually not possible in the absence of the required toxicological data.
ACCESSION #
14392594

 

Related Articles

  • Multiplex Measurements. Grow, Matthew; Sekinger, Edward // Drug Discovery & Development;Oct2011, Vol. 14 Issue 10, p16 

    The article focuses on the increasing demand for rapid low-cost drug discovery testing in the U.S. pharmaceutical industry. It notes the use of cost-effective mid-plex gene expression platforms and chemistries that could potentially offer additional approach drug discovery. Moreover, it mentions...

  • Translation of New Technologies: From Basic Research to Drug Discovery and Development. Bhogal, Nirmala; Balls, Michael // Current Drug Discovery Technologies;Sep2008, Vol. 5 Issue 3, p250 

    Despite increasing investment in drug discovery and development, only around one in every ten new medicinal products that progresses to clinical testing ever reach from the registration stage. Approximately half of all drug failures are attributed to problems with efficacy and toxicity not...

  • Managing the challenge of chemically reactive metabolites in drug development. Park, B. Kevin; Boobis, Alan; Clarke, Stephen; Goldring, Chris E. P.; Jones, David; Kenna, J. Gerry; Lambert, Craig; Laverty, Hugh G.; Naisbitt, Dean J.; Nelson, Sidney; Nicoll-Griffith, Deborah A.; Obach, R. Scott; Routledge, Philip; Smith, Dennis A.; Tweedie, Donald J.; Vermeulen, Nico; Williams, Dominic P.; Wilson, Ian D.; Baillie, Thomas A. // Nature Reviews Drug Discovery;Apr2011, Vol. 10 Issue 4, p292 

    The normal metabolism of drugs can generate metabolites that have intrinsic chemical reactivity towards cellular molecules, and therefore have the potential to alter biological function and initiate serious adverse drug reactions. Here, we present an assessment of the current approaches used for...

  • Regulatory Forum Opinion Piece*: Differences between Protein-based Biologic Products (Biotherapeutics) and Chemical Entities (Small Molecules) of Relevance to the Toxicologic Pathologist. Leach, Michael W. // Toxicologic Pathology;Jan2013, Vol. 41 Issue 1, p128 

    With the advances in cell culture methodologies and molecular biology that have occurred over the past several decades, biologics have become as common as small molecules within the portfolios of the pharmaceutical industry. Toxicologic pathologists should be aware of some of the fundamental...

  • "me-toos," "me-agains," and the risk of drugs. Joyce, C.R.B. // British Medical Journal;7/26/1980, Vol. 281 Issue 6235, p286 

    Discusses the need for vigilance on drug industry in Great Britain. Major toxic effect by marketed drugs; Effects of drugs on epidemiology; Universal package leaflet on drugs.

  • Different biokinetics of nanomedicines linking to their toxicity; an overview. Mostafalou, Sara; Mohammadi, Hamidreza; Ramazani, Ali; Abdollahi, Mohammad // DARU;2013, Vol. 21 Issue 2, p1 

    In spite of the extreme rise to the knowledge of nanotechnology in pharmaceutical sciences, there are currently limited experimental works studying the interactions between nanoparticles (NPs) and the biological system. Adjustment of size and surface area plays the main role in the reaction...

  • In Vitro Toxicology Testing: The Time Is Now. Watson, John // Drug Discovery & Development;Feb2002, Vol. 5 Issue 2, p13 

    Focuses on the need for cost-effective, efficient method of determining toxicity early in the drug development cycle. Efficacy of in vitro assays with permanent cell lines; Automation of tetrazolium assay and adenosine triphosphate assays; Interest in mechanistic toxicity assays.

  • Arsenic Toxicity and Possible Treatment Strategies: Some Recent Advancement. Flora, Govinder J. S. // Current Trends in Biotechnology & Pharmacy;Jul2012, Vol. 6 Issue 3, p280 

    Arsenic toxicity has emerged as a global concern of prevalence especially in various Asian regions, highlighted with 130 million population at risk in India and Bangladesh. Arsenic toxicity has been associated with numerous health effects affecting almost every organ system. These adverse...

  • Further Reading.  // PharmaWatch: Monthly Review;Jan2009, Vol. 8 Issue 1, p40 

    The article lists several books related to pharmaceutical industry including "Phamaceutical Company Outlook to 2013," "Divestment Strategies: Pharma is divesting in order to grow," an "Forecast Insight: Antithrombotics - Market growth dependent on new agents."

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics